Latest Whitepapers

Just when you thought it couldn’t be done, the Thermo Scientific™ Neoma™ MC-ICP-MS raises the bar. Building on the strength of our multicollector technology, this next generation system delivers all the advantages of high-precision isotope ratio analysis, but none of the limitations.

Harnessing decades of continuous improvement, the DELTA Q IRMS is the pinnacle of isotope analysis, providing high quality, robust data on an easy-to-use innovative Thermo Scientific™ Qtegra™ Intelligent Scientific Data Solution software platform.

Now, more than ever, we need to take responsibility for our actions. As global levels of atmospheric CO2 continue to increase, we need to be making positive steps forward to reduce our emissions and remove CO2 from the atmosphere.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.

Download this whitepaper to discover how to overcome the limitations of PCR testing, how RT-qPCR will impact diagnostics both in lab and at point of care and how RT-qPCR is driving new methods and applications.

Tandem mass spectrometry (MS/MS) has evolved as one of the most valuable analytical tools available to modern scientists and enables the identification, structural elucidation and quantitation of compounds.

At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects.

Download this whitepaper to learn more about the analysis of varied particle sizes, sampling techniques and automation options for infrared microscopy.

Development of a manufacturing process for a biotherapeutic that ensures consistent quality, purity and safety is a critical step in successfully developing the drug, getting it approved by regulatory agencies, and bringing it to the market.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy.